English
Stock of the day
4D Medical
Adoption of 4D Medical’s CT:VQ technology by UC San Diego Health drives shares higher, reflecting early US traction despite high valuations.
(AI video summary)
This video was created on 7 January 2026 for IG audiences by ausbiz.
ASX code: 4DX
4D Medical rallies on US hospital deal
Shares in 4DMedical rose 13.6% to a record high after the company secured a new United States (US) hospital contract, strengthening its position in healthcare technology.
The company confirmed University of California San Diego Health has adopted its CT:VQ lung imaging software, becoming the fourth US academic medical centre to implement the technology. The agreement follows approval from the US Food and Drug Administration (FDA) just four months ago.
Growth story versus valuation
Since listing around six years ago at approximately $0.73, 4D Medical shares have risen to around $4.77, valuing the company at about $2.4 billion. This compares with annual revenue of roughly $7 million, underscoring expectations of strong future growth.
Investment outlook
Analysts caution the valuation has moved ahead of near-term fundamentals, with consensus estimates suggesting fair value closer to $2.50 per share. On forward assumptions, the stock is trading on elevated revenue multiples, reflecting optimism well into future years.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
Follow us online:
